EMBECTA CORP. Deferred Income Tax Expense (Benefit)
EMBECTA CORP. (EMBC) reported Deferred Income Tax Expense (Benefit) of $12.10 million for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-08-07
- EMBECTA CORP. deferred income tax expense (benefit) for the quarter ending 2026-06-30 was $2.30M, a 63.49% decline year-over-year.
- EMBECTA CORP. deferred income tax expense (benefit) for the quarter ending 2026-03-31 was $6.40M, a 93.94% increase year-over-year.
- EMBECTA CORP. deferred income tax expense (benefit) for the quarter ending 2025-12-31 was $3.40M, a 47.83% increase year-over-year.
- EMBECTA CORP. deferred income tax expense (benefit) for the quarter ending 2025-09-30 was $5.70M.
- EMBECTA CORP. deferred income tax expense (benefit) for fiscal 2025 was $17.60M.
- EMBECTA CORP. deferred income tax expense (benefit) for fiscal 2024 was -$70.60M, a 593.71% decline from fiscal 2023.
- EMBECTA CORP. deferred income tax expense (benefit) for fiscal 2023 was $14.30M.
- EMBECTA CORP. deferred income tax expense (benefit) for fiscal 2022 was -$26.50M.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-07 | $8.70M derived: sum of 2 quarters · filed 2026-08-07 | $12.10M 10-Q · filed 2026-08-07 | $17.80M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $6.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-05 | $9.80M 10-Q · filed 2026-05-05 | $15.50M derived: sum of 3 quarters · filed 2026-05-05 | $21.80M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $3.40M 10-Q · filed 2026-02-05 | $9.10M derived: sum of 2 quarters · filed 2026-02-05 | $15.40M derived: sum of 3 quarters · filed 2026-08-07 | $18.70M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-09-30 | $5.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $12.00M derived: sum of 2 quarters · filed 2026-08-07 | $15.30M derived: sum of 3 quarters · filed 2026-08-07 | $17.60M 10-K · filed 2025-11-25 |
| 2025-06-30 | $6.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-07 | $9.60M derived: sum of 2 quarters · filed 2026-08-07 | $11.90M 10-Q · filed 2026-08-07 | -$15.80M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $3.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-05 | $5.60M 10-Q · filed 2026-05-05 | -$22.10M derived: sum of 3 quarters · filed 2026-05-05 | -$25.40M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $2.30M 10-Q · filed 2026-02-05 | -$25.40M derived: sum of 2 quarters · filed 2026-02-05 | -$28.70M derived: sum of 3 quarters · filed 2026-02-05 | -$51.30M derived: sum of 4 quarters · filed 2026-02-05 |
| 2024-09-30 | -$27.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | -$31.00M derived: sum of 2 quarters · filed 2025-11-25 | -$53.60M derived: sum of 3 quarters · filed 2025-11-25 | -$70.60M 10-K · filed 2025-11-25 |
| 2024-06-30 | -$3.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-08 | -$25.90M derived: sum of 2 quarters · filed 2025-08-08 | -$42.90M 10-Q · filed 2025-08-08 | -$30.80M derived: sum of 4 quarters · filed 2025-11-25 |
| 2024-03-31 | -$22.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-05-09 | -$39.60M 10-Q · filed 2025-05-09 | -$27.50M derived: sum of 3 quarters · filed 2025-11-25 | -$26.50M derived: sum of 4 quarters · filed 2025-11-25 |
| 2023-12-31 | -$17.00M 10-Q · filed 2025-02-06 | -$4.90M derived: sum of 2 quarters · filed 2025-11-25 | -$3.90M derived: sum of 3 quarters · filed 2025-11-25 | -$4.10M derived: sum of 4 quarters · filed 2025-11-25 |
| 2023-09-30 | $12.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $13.10M derived: sum of 2 quarters · filed 2025-11-25 | $12.90M derived: sum of 3 quarters · filed 2025-11-25 | $14.30M 10-K · filed 2025-11-25 |
| 2023-06-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-08-09 | $800.00K derived: sum of 2 quarters · filed 2024-08-09 | $2.20M 10-Q · filed 2024-08-09 | -$24.70M derived: sum of 4 quarters · filed 2024-12-11 |
| 2023-03-31 | -$200.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-05-09 | $1.20M 10-Q · filed 2024-05-09 | -$25.70M derived: sum of 3 quarters · filed 2024-12-11 | -$25.30M derived: sum of 4 quarters · filed 2024-12-11 |
| 2022-12-31 | $1.40M 10-Q · filed 2024-02-09 | -$25.50M derived: sum of 2 quarters · filed 2024-12-11 | -$25.10M derived: sum of 3 quarters · filed 2024-12-11 | -$25.10M derived: sum of 4 quarters · filed 2024-12-11 |
| 2022-09-30 | -$26.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-11 | -$26.50M derived: sum of 2 quarters · filed 2024-12-11 | -$26.50M derived: sum of 3 quarters · filed 2024-12-11 | -$26.50M 10-K · filed 2024-12-11 |
| 2022-06-30 | $400.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-08-08 | $400.00K derived: sum of 2 quarters · filed 2023-08-08 | $400.00K 10-Q · filed 2023-08-08 | -$2.40M derived: sum of 4 quarters · filed 2023-11-29 |
| 2022-03-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-05-12 | $0.00 10-Q · filed 2023-05-12 | -$2.80M derived: sum of 3 quarters · filed 2023-11-29 | |
| 2021-12-31 | $0.00 10-Q · filed 2023-02-14 | -$2.80M derived: sum of 2 quarters · filed 2023-11-29 | ||
| 2021-09-30 | -$2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-29 | -$2.80M 10-K · filed 2023-11-29 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-15 | |||
| 2020-09-30 | -$2.20M 10-K · filed 2022-12-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |